Cargando…

Comparing assessment frameworks for cancer drugs between Canada and Europe: What can we learn from the differences?

The increasing burden of costs associated with novel cancer therapies is becoming untenable. In Europe and Canada, assessment frameworks have been developed to attribute value to novel therapies and ultimately facilitate access to cancer drug funding. A review of the two frameworks has not previousl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheung, Matthew C, Chan, Kelvin KW, Sabharwal, Mona, Fields, Anthony, Chambers, Alexandra, Evans, William K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	ESMO Open 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703384/ https://www.ncbi.nlm.nih.gov/pubmed/29209520 http://dx.doi.org/10.1136/esmoopen-2016-000124

Ejemplares similares

Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?
por: Hoch, Jeffrey S., et al.
Publicado: (2015)

The impact of pricing strategy on the costs of oral anti‐cancer drugs
por: Truong, Judy, et al.
Publicado: (2019)

How can we increase participation in pandemic research in Canada?
por: Tsang, Jennifer L. Y., et al.
Publicado: (2021)

Geriatric Radiation Oncology: What We Know and What Can We Do Better?
por: Roeder, Falk, et al.
Publicado: (2023)

Loneliness, social isolation and social relationships: what are we measuring? A novel framework for classifying and comparing tools
por: Valtorta, Nicole K, et al.
Publicado: (2016)

Replications in Comparative Cognition: What Should We Expect and How Can We Improve?
por: Farrar, Benjamin G., et al.
Publicado: (2020)

Assessing health care in Canada's North: what can we learn from national and regional surveys?
por: Young, T. Kue, et al.
Publicado: (2015)

What Can We Demonstrate?
por: Mills, G. A.
Publicado: (1896)

Reversal Agents: What We Have and What We Can Expect
por: Ruff, Christian T.
Publicado: (2018)

Enhancer RNA: What we know and what we can achieve
por: Han, Zhenzhen, et al.
Publicado: (2022)

What we can and what we cannot see with extracellular multielectrodes
por: Chintaluri, Chaitanya, et al.
Publicado: (2021)

The origin of life: what we know, what we can know and what we will never know
por: Pross, Addy, et al.
Publicado: (2013)

Suicide epidemic in Malawi: what can we do?
por: Banda, Gift Treighcy, et al.
Publicado: (2021)

Clinical experience with Zarzio® in Europe: what have we learned?
por: Gascón, Pere, et al.
Publicado: (2013)

Impact of smoking on health system costs among cancer patients in a retrospective cohort study in Ontario, Canada
por: Isaranuwatchai, Wanrudee, et al.
Publicado: (2019)

Creating healthy workplaces in healthcare: Are we delaying progress by focusing on what we can do rather than what we should do?
por: Montgomery, Anthony, et al.
Publicado: (2023)

“Doing What We Can with What We Have”: Examining the Role of Local Government in Poverty Management during the COVID-19 Pandemic
por: Long, Fiona, et al.
Publicado: (2023)

Quasicrystals: What do we know? What do we want to know? What can we know?
por: Steurer, Walter
Publicado: (2018)

How we remember what we can do
por: Declerck, Gunnar
Publicado: (2015)

What Can We Do to Be Saved?
por: Visanska, Samuel A.
Publicado: (1913)

A qualitative study of the current state of heart failure community care in Canada: what can we learn for the future?
por: Hayes, Sean M., et al.
Publicado: (2015)

What Can Canada Learn From Accountable Care Organizations: A Comparative Policy Analysis
por: Peckham, Allie, et al.
Publicado: (2022)

First-Episode Psychosis care in Central Europe: What we have learned and what we still need to do
por: Réthelyi, J.
Publicado: (2022)

The emergence of Brucella canis as a public health threat in Europe: what we know and what we need to learn
por: Djokic, Vitomir, et al.
Publicado: (2023)

What can we teach Lymnaea and what can Lymnaea teach us?
por: Rivi, Veronica, et al.
Publicado: (2021)

INDIAN PSYCHIATRY AT THE CROSSROADS - WHAT WE CAN DO WITH WHAT WE HAVE?1
por: Channabasavanna, S.M.
Publicado: (1992)

The cancer-obesity connection: what do we know and what can we do?
por: Riboli, Elio
Publicado: (2014)

Management of Achilles and patellar tendinopathy: what we know, what we can do
por: Aicale, Rocco, et al.
Publicado: (2020)

Isolated Nocturnal Hypertension: What Do We Know and What Can We Do?
por: Tadic, Marijana, et al.
Publicado: (2020)

Hepatitis of unknown etiology in children: What we know and what we can do?
por: Zhu, Mingyu, et al.
Publicado: (2022)

Ketamine plus Alcohol: What We Know and What We Can Expect about This
por: Kobayashi, Natalia Harumi Correa, et al.
Publicado: (2022)

Quality of End-of-Life Care in Gastrointestinal Cancers: A 13-Year Population-Based Retrospective Analysis in Ontario, Canada
por: Lees, Caitlin SR, et al.
Publicado: (2022)

The FIRE AND ICE Trial: What We Know, What We Can Still Learn, and What We Need to Address in the Future
por: Kuck, Karl‐Heinz, et al.
Publicado: (2018)

Incidence rates of suicide attempts and self-harm in Europe. What can we learn? A systematic review and meta-analysis
por: Jakobsen, S., et al.
Publicado: (2022)

Cosmic debris: what it is and what we can do about it
por: Powell, Jonathan
Publicado: (2017)

Virtual nutrition consultation: what can we learn from the COVID-19 pandemic?
por: Kaufman-Shriqui, Vered, et al.
Publicado: (2021)

Quality and Outcomes Framework: what have we learnt?
por: Roland, Martin, et al.
Publicado: (2016)

Understanding of Adventitious Root Formation: What Can We Learn From Comparative Genetics?
por: Mhimdi, Mariem, et al.
Publicado: (2020)

Schottky noise: what can we observe?
por: Baird, S A
Publicado: (1989)

Schottky noise what can we observe ?
por: Baird, S
Publicado: (1989)

Cannot write session to /tmp/vufind_sessions/sess_2msh2ekig2e8g9tgja9f9df40c